← All Xenon Pharmaceuticals INC filings

Xenon Pharmaceuticals INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
XENE
Xenon Pharmaceuticals INC
10-K: Xenon Pharmaceuticals Advances Pipeline, Reports Q4 2025 Losses
Xenon Pharmaceuticals Inc. continues to advance its late-stage clinical pipeline, including azetukalner for epilepsy and depression, while reporting increased net losses and R&D expenses for fiscal year 2025.
NASDAQ
XENE
Xenon Pharmaceuticals INC
10-K: Xenon Pharmaceuticals Reports Full Year 2024 Results, Highlights Azetukalner Progress
Xenon Pharmaceuticals' 10-K filing details the company's financial results for 2024 and provides updates on its pipeline, particularly the progress of azetukalner in epilepsy and neuropsychiatric disorders.
NASDAQ
XENE
Xenon Pharmaceuticals INC
10-K: Xenon Pharmaceuticals Details Share Structure and Corporate Governance in 10-K Filing
Xenon Pharmaceuticals' 10-K filing outlines the details of its common and preferred shares, along with corporate governance and regulatory compliance.